Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
5
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
5
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
5
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
deals
ipo
startups
alzheimer's disease
cancer immunotherapy
crispr
gilead sciences
medicare
venture capital
abbvie
What
bio
roundup
companies
covid
drug
gene
ipo
medicines
new
price
talk
acquisitions
activity
alzheimer’s
announced
approval
approvals
becker
billions
biogen
biogen’s
biopharmaceutical
ceo
clamped
collabs
convo
daniel
deal
delays
developing
different
dollars
earlier
eaton
economic
fail
failures
fast
fda
gilead
Language
unset
Current search:
novartis
×
biogen
×
" seattle blog main "
×
cancer
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More